Market closedNon-fractional

Phathom Pharmaceuticals/PHAT

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Phathom Pharmaceuticals

Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.

Ticker

PHAT

Sector

Healthcare

Trading on

NASDAQ

Industry

Pharmaceuticals

Headquarters

Florham Park, United States

Employees

452

PHAT Metrics

BasicAdvanced
$600M
Market cap
-
P/E ratio
-$4.46
EPS
0.67
Beta
-
Dividend rate
$600M
0.67
7.831
7.504
-310.797
-322.385
-4.15%
-51.74%
206.65%
218.49
-4.01
-4.01
-3.366
-7.99%
1.98%

What the Analysts think about PHAT

Analyst Ratings

Majority rating from 9 analysts.
Buy

PHAT Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-4,357.89% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$1.9M
216.67%
Net income
-$83M
4.15%
Profit margin
-4,357.89%
-67.11%

PHAT Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 8.47%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.84
-$0.76
-$1.39
-$1.42
-
Expected
-$0.98
-$0.89
-$1.08
-$1.31
-$1.38
Surprise
-14.16%
-14.74%
29.06%
8.47%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Phathom Pharmaceuticals stock?

Phathom Pharmaceuticals (PHAT) has a market cap of $600M as of July 05, 2024.

What is the P/E ratio for Phathom Pharmaceuticals stock?

The price to earnings (P/E) ratio for Phathom Pharmaceuticals (PHAT) stock is 0 as of July 05, 2024.

Does Phathom Pharmaceuticals stock pay dividends?

No, Phathom Pharmaceuticals (PHAT) stock does not pay dividends to its shareholders as of July 05, 2024.

When is the next Phathom Pharmaceuticals dividend payment date?

Phathom Pharmaceuticals (PHAT) stock does not pay dividends to its shareholders.

What is the beta indicator for Phathom Pharmaceuticals?

Phathom Pharmaceuticals (PHAT) has a beta rating of 0.67. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy or sell Phathom Pharmaceuticals stock

Buy or sell Phathom Pharmaceuticals stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing